{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:37:51Z","timestamp":1794591471529,"version":"4.9.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Practice guidelines provide clear evidence-based recommendations for the use of drug therapy to manage pain, agitation, and delirium associated with critical illness. Dosing recommendations however are often based on strategies used in patients with normal body habitus. Recommendations specific to critically ill patients with extreme obesity are lacking. Nonetheless, clinicians must craft dosing regimens for this population. This paper is intended to help clinicians design initial dosing regimens for medications commonly used in the management of pain, agitation, and delirium in critically ill patients with extreme obesity. A detailed literature search was conducted with an emphasis on obesity, pharmacokinetics, and dosing. Relevant manuscripts were reviewed and strategies for dosing are provided.<\/jats:p>","DOI":"10.1186\/s13054-020-03040-z","type":"journal-article","created":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T08:05:46Z","timestamp":1591603546000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Drug dosing in the critically ill obese patient\u2014a focus on sedation, analgesia, and delirium"],"prefix":"10.1186","volume":"24","author":[{"given":"Brian L.","family":"Erstad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9054-8218","authenticated-orcid":false,"given":"Jeffrey F.","family":"Barletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,8]]},"reference":[{"issue":"7","key":"3040_CR1","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/ajhp\/zxaa022","volume":"77","author":"C Eastman","year":"2020","unstructured":"Eastman C, Erstad BL. Availability of information for dosing commonly used medications in special ICU populations. Am J Health-Syst Pharmacy. 2020;77(7):529\u201334.","journal-title":"Am J Health-Syst Pharmacy"},{"issue":"2","key":"3040_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.5492\/wjccm.v4.i2.139","volume":"4","author":"BL Erstad","year":"2015","unstructured":"Erstad BL. Designing drug regimens for special intensive care unit populations. World J Critical Care Med. 2015;4(2):139\u201351.","journal-title":"World J Critical Care Med"},{"issue":"9","key":"3040_CR3","doi-asserted-by":"publisher","first-page":"e825","DOI":"10.1097\/CCM.0000000000003299","volume":"46","author":"JW Devlin","year":"2018","unstructured":"Devlin JW, Skrobik Y, Gelinas C, Needham DM, Slooter AJC, Pandharipande PP, et al. Clinical practice guidelines for the prevention and management of pain, agitation\/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018;46(9):e825\u2013e73.","journal-title":"Crit Care Med"},{"key":"3040_CR4","doi-asserted-by":"crossref","unstructured":"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074-82. https:\/\/www.drugbank.ca\/. Accessed Oct 2019.","DOI":"10.1093\/nar\/gkx1037"},{"issue":"4","key":"3040_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.5811\/westjem.2010.11.1922","volume":"12","author":"D Kimball","year":"2011","unstructured":"Kimball D, Kincaide RC, Ives C, Henderson S. Rapid sequence intubation from the Patient's perspective. West J Emerg Med. 2011;12(4):365\u20137.","journal-title":"West J Emerg Med"},{"issue":"5","key":"3040_CR6","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2165\/11598930-000000000-00000","volume":"51","author":"SC McLeay","year":"2012","unstructured":"McLeay SC, Morrish GA, Kirkpatrick CM, Green B. The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007. Clin Pharmacokinet. 2012;51(5):319\u201330.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"3040_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1365-2125.2004.02157.x","volume":"58","author":"B Green","year":"2004","unstructured":"Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol. 2004;58(2):119\u201333.","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"3040_CR8","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","volume":"44","author":"S Janmahasatian","year":"2005","unstructured":"Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051\u201365.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"3040_CR9","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.clnu.2016.09.013","volume":"36","author":"LL Moisey","year":"2017","unstructured":"Moisey LL, Mourtzakis M, Kozar RA, Compher C, Heyland DK. Existing equations to estimate lean body mass are not accurate in the critically ill: Results of a multicenter observational study. Clin Nutri (Edinburgh, Scotland). 2017;36(6):1701\u20136.","journal-title":"Clin Nutri (Edinburgh, Scotland)"},{"issue":"8","key":"3040_CR10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/BF03261929","volume":"51","author":"I Mahmood","year":"2012","unstructured":"Mahmood I. Prediction of clearance and volume of distribution in the obese from normal weight subjects : an allometric approach. Clin Pharmacokinet. 2012;51(8):527\u201342.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"3040_CR11","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/j.1875-9114.2012.01108.x","volume":"32","author":"MP Pai","year":"2012","unstructured":"Pai MP. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacotherapy. 2012;32(9):856\u201368.","journal-title":"Pharmacotherapy."},{"issue":"1","key":"3040_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/014860710302700189","volume":"27","author":"GL Jensen","year":"2003","unstructured":"Jensen GL, Friedmann JM, Henry DK, Skipper A, Beiler E, Porter C, et al. Noncompliance with body weight measurement in tertiary care teaching hospitals. JPEN J Parenter Enteral Nutr. 2003;27(1):89\u201390.","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"1","key":"3040_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/j.1875-9114.1982.tb03172.x","volume":"2","author":"R Bennett","year":"1982","unstructured":"Bennett R, Batenhorst R, Graves DA, Foster TS, Griffen WO, Wright BD. Variation in postoperative analgesic requirements in the morbidly obese following gastric bypass surgery. Pharmacotherapy. 1982;2(1):50\u20133.","journal-title":"Pharmacotherapy."},{"issue":"2","key":"3040_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/emermed-2012-202168","volume":"31","author":"AE Patanwala","year":"2014","unstructured":"Patanwala AE, Holmes KL, Erstad BL. Analgesic response to morphine in obese and morbidly obese patients in the emergency department. Emerg Med J. 2014;31(2):139\u201342.","journal-title":"Emerg Med J"},{"key":"3040_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0022-3999(85)90007-8","volume":"29","author":"CSW Rand","year":"1985","unstructured":"Rand CSW, Kuldau JM, Yost RL. Obesity and post-operative pain. J Psychosom Res. 1985;29:43\u20138.","journal-title":"J Psychosom Res"},{"key":"3040_CR16","doi-asserted-by":"crossref","unstructured":"Xia S, Choe D, Hernandez L, Birnbaum A. Does initial hydromorphone relieve pain best if dosing is fixed or weight based? Annals of emergency medicine. 2014;63(6):692\u20138.e4.","DOI":"10.1016\/j.annemergmed.2013.10.003"},{"issue":"3","key":"3040_CR17","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1097\/00000542-199809000-00004","volume":"89","author":"TD Egan","year":"1998","unstructured":"Egan TD, Huizinga B, Gupta SK, Jaarsma RL, Sperry RJ, Yee JB, et al. Remifentanil pharmacokinetics in obese versus lean patients. Anesthesiology. 1998;89(3):562\u201373.","journal-title":"Anesthesiology."},{"issue":"4","key":"3040_CR18","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/bja\/aes211","volume":"109","author":"O Perus","year":"2012","unstructured":"Perus O, Marsot A, Ramain E, Dahman M, Paci A, Raucoules-Aime M, et al. Performance of alfentanil target-controlled infusion in normal and morbidly obese female patients. Br J Anaesth. 2012;109(4):551\u201360.","journal-title":"Br J Anaesth"},{"issue":"6","key":"3040_CR19","first-page":"790","volume":"73","author":"AE Schwartz","year":"1991","unstructured":"Schwartz AE, Matteo RS, Ornstein E, Young WL, Myers KJ. Pharmacokinetics of sufentanil in obese patients. Anesth Analg. 1991;73(6):790\u20133.","journal-title":"Anesth Analg"},{"issue":"3","key":"3040_CR20","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/00000542-200409000-00008","volume":"101","author":"K Shibutani","year":"2004","unstructured":"Shibutani K, Inchiosa MA Jr, Sawada K, Bairamian M. Accuracy of pharmacokinetic models for predicting plasma fentanyl concentrations in lean and obese surgical patients: derivation of dosing weight (\u201cpharmacokinetic mass\u201d). Anesthesiology. 2004;101(3):603\u201313.","journal-title":"Anesthesiology."},{"issue":"3","key":"3040_CR21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/bja\/aei195","volume":"95","author":"K Shibutani","year":"2005","unstructured":"Shibutani K, Inchiosa MA Jr, Sawada K, Bairamian M. Pharmacokinetic mass of fentanyl for postoperative analgesia in lean and obese patients. Br J Anaesth. 2005;95(3):377\u201383.","journal-title":"Br J Anaesth"},{"issue":"1","key":"3040_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/00000542-200301000-00014","volume":"98","author":"G Slepchenko","year":"2003","unstructured":"Slepchenko G, Simon N, Goubaux B, Levron JC, Le Moing JP, Raucoules-Aime M. Performance of target-controlled sufentanil infusion in obese patients. Anesthesiology. 2003;98(1):65\u201373.","journal-title":"Anesthesiology."},{"issue":"12","key":"3040_CR23","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s40262-017-0544-2","volume":"56","author":"S de Hoogd","year":"2017","unstructured":"de Hoogd S, Valitalo PAJ, Dahan A, van Kralingen S, Coughtrie MMW, van Dongen EPA, et al. Influence of morbid obesity on the pharmacokinetics of morphine, morphine-3-glucuronide, and morphine-6-glucuronide. Clin Pharmacokinet. 2017;56(12):1577\u201387.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"3040_CR24","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1213\/ANE.0000000000003549","volume":"127","author":"C Cozowicz","year":"2018","unstructured":"Cozowicz C, Chung F, Doufas AG, Nagappa M, Memtsoudis SG. Opioids for acute pain management in patients with obstructive sleep apnea: a systematic review. Anesth Analg. 2018;127(4):988\u20131001.","journal-title":"Anesth Analg"},{"issue":"1","key":"3040_CR25","first-page":"159","volume":"240","author":"JC Scott","year":"1987","unstructured":"Scott JC, Stanski DR. Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation. J Pharmacol Exp Ther. 1987;240(1):159\u201366.","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"3040_CR26","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/anae.13101","volume":"70","author":"CE Nightingale","year":"2015","unstructured":"Nightingale CE, Margarson MP, Shearer E, Redman JW, Lucas DN, Cousins JM, et al. Peri-operative management of the obese surgical patient 2015: association of anaesthetists of Great Britain and Ireland society for obesity and bariatric anaesthesia. Anaesthesia. 2015;70(7):859\u201376.","journal-title":"Anaesthesia."},{"issue":"10","key":"3040_CR27","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/art.1780281006","volume":"28","author":"DR Abernethy","year":"1985","unstructured":"Abernethy DR, Greenblatt DJ. Ibuprofen disposition in obese individuals. Arthritis Rheum. 1985;28(10):1117\u201321.","journal-title":"Arthritis Rheum"},{"key":"3040_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2253-14-77","volume":"14","author":"K Allegaert","year":"2014","unstructured":"Allegaert K, Olkkola KT, Owens KH, Van de Velde M, de Maat MM, Anderson BJ. Covariates of intravenous paracetamol pharmacokinetics in adults. BMC Anesthesiol. 2014;14:77.","journal-title":"BMC Anesthesiol"},{"issue":"2","key":"3040_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.annemergmed.2016.10.014","volume":"70","author":"S Motov","year":"2017","unstructured":"Motov S, Yasavolian M, Likourezos A, Pushkar I, Hossain R, Drapkin J, et al. Comparison of intravenous ketorolac at three single-dose regimens for treating acute pain in the emergency department: a randomized controlled trial. Ann Emerg Med. 2017;70(2):177\u201384.","journal-title":"Ann Emerg Med"},{"key":"3040_CR30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/bs.apha.2019.01.003","volume":"85","author":"J Allard","year":"2019","unstructured":"Allard J, Le Guillou D, Begriche K, Fromenty B. Drug-induced liver injury in obesity and nonalcoholic fatty liver disease. Adv Pharmacol (San Diego, Calif). 2019;85:75\u2013107.","journal-title":"Adv Pharmacol (San Diego, Calif)"},{"issue":"1","key":"3040_CR31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/pds.4339","volume":"27","author":"S Chomchai","year":"2018","unstructured":"Chomchai S, Chomchai C. Being overweight or obese as a risk factor for acute liver injury secondary to acute acetaminophen overdose. Pharmacoepidemiol Drug Saf. 2018;27(1):19\u201324.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3040_CR32","doi-asserted-by":"crossref","unstructured":"Hurth KP, Jaworski A, Thomas KB, Kirsch WB, Rudoni MA, Wohlfarth KM. The Reemergence of ketamine for treatment in critically ill adults. Critical Care Med. 2020;48(6):899-911.","DOI":"10.1097\/CCM.0000000000004335"},{"issue":"1","key":"3040_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/bja\/53.1.27","volume":"53","author":"JA Clements","year":"1981","unstructured":"Clements JA, Nimmo WS. Pharmacokinetics and analgesic effect of ketamine in man. Br J Anaesth. 1981;53(1):27\u201330.","journal-title":"Br J Anaesth"},{"issue":"3","key":"3040_CR34","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/ALN.0b013e3181ed09a2","volume":"113","author":"EF Domino","year":"2010","unstructured":"Domino EF. Taming the ketamine tiger. 1965. Anesthesiology. 2010;113(3):678\u201384.","journal-title":"Anesthesiology."},{"issue":"2","key":"3040_CR35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/bja\/aeg028","volume":"90","author":"Y Hijazi","year":"2003","unstructured":"Hijazi Y, Bodonian C, Bolon M, Salord F, Boulieu R. Pharmacokinetics and haemodynamics of ketamine in intensive care patients with brain or spinal cord injury. Br J Anaesth. 2003;90(2):155\u201360.","journal-title":"Br J Anaesth"},{"issue":"4","key":"3040_CR36","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1097\/00000542-199304000-00008","volume":"78","author":"F Servin","year":"1993","unstructured":"Servin F, Farinotti R, Haberer JP, Desmonts JM. Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide. A clinical and pharmacokinetic study. Anesthesiology. 1993;78(4):657\u201365.","journal-title":"Anesthesiology."},{"issue":"8","key":"3040_CR37","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1034\/j.1399-6576.1999.430810.x","volume":"43","author":"K Hirota","year":"1999","unstructured":"Hirota K, Ebina T, Sato T, Ishihara H, Matsuki A. Is total body weight an appropriate predictor for propofol maintenance dose? Acta Anaesthesiol Scand. 1999;43(8):842\u20134.","journal-title":"Acta Anaesthesiol Scand"},{"issue":"8 Pt 1","key":"3040_CR38","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/j.1399-6576.1996.tb04555.x","volume":"40","author":"D Chassard","year":"1996","unstructured":"Chassard D, Berrada K, Bryssine B, Guiraud M, Bouletreau P. Influence of body compartments on propofol induction dose in female patients. Acta Anaesthesiol Scand. 1996;40(8 Pt 1):889\u201391.","journal-title":"Acta Anaesthesiol Scand"},{"issue":"10","key":"3040_CR39","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1124\/dmd.116.071605","volume":"44","author":"D Dong","year":"2016","unstructured":"Dong D, Peng X, Liu J, Qian H, Li J, Wu B. Morbid obesity alters both pharmacokinetics and pharmacodynamics of propofol: dosing recommendation for anesthesia induction. Drug Metabolism Disposition. 2016;44(10):1579\u201383.","journal-title":"Drug Metabolism Disposition"},{"issue":"1","key":"3040_CR40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1213\/ANE.0b013e3181f6d9c0","volume":"113","author":"J Ingrande","year":"2011","unstructured":"Ingrande J, Brodsky JB, Lemmens HJ. Lean body weight scalar for the anesthetic induction dose of propofol in morbidly obese subjects. Anesth Analg. 2011;113(1):57\u201362.","journal-title":"Anesth Analg"},{"issue":"1","key":"3040_CR41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0310057X9101900110","volume":"19","author":"K Leslie","year":"1991","unstructured":"Leslie K, Crankshaw DP. Lean tissue mass is a useful predictor of induction dose requirements for propofol. Anaesth Intensive Care. 1991;19(1):57\u201360.","journal-title":"Anaesth Intensive Care"},{"issue":"2","key":"3040_CR42","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3109\/03009739309179313","volume":"98","author":"L Lind","year":"1993","unstructured":"Lind L, Johansson S, Ekman K. The influence of obesity and fat distribution on induction and maintenance doses of propofol. (short communication). Ups J Med Sci. 1993;98(2):187\u20138.","journal-title":"Ups J Med Sci"},{"issue":"7","key":"3040_CR43","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1007\/s11095-009-9873-7","volume":"26","author":"SC McLeay","year":"2009","unstructured":"McLeay SC, Morrish GA, Kirkpatrick CM, Green B. Encouraging the move towards predictive population models for the obese using propofol as a motivating example. Pharm Res. 2009;26(7):1626\u201334.","journal-title":"Pharm Res"},{"issue":"4","key":"3040_CR44","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/aas.13039","volume":"62","author":"AM Araujo","year":"2018","unstructured":"Araujo AM, Machado HS, Falcao AC, Soares-da-Silva P. Reliability of body-weight scalars on the assessment of propofol induction dose in obese patients. Acta Anaesthesiol Scand. 2018;62(4):464\u201373.","journal-title":"Acta Anaesthesiol Scand"},{"issue":"2","key":"3040_CR45","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.aat.2013.06.009","volume":"51","author":"F Lam","year":"2013","unstructured":"Lam F, Liao CC, Lee YJ, Wang W, Kuo CJ, Lin CS. Different dosing regimens for propofol induction in obese patients. Acta Anaesthesiol Taiwanica : Off J Taiwan Soc Anesthesiol. 2013;51(2):53\u20137.","journal-title":"Acta Anaesthesiol Taiwanica : Off J Taiwan Soc Anesthesiol"},{"issue":"4","key":"3040_CR46","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1093\/bja\/aeq195","volume":"105","author":"LI Cortinez","year":"2010","unstructured":"Cortinez LI, Anderson BJ, Penna A, Olivares L, Munoz HR, Holford NH, et al. Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model. Br J Anaesth. 2010;105(4):448\u201356.","journal-title":"Br J Anaesth"},{"issue":"6","key":"3040_CR47","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1213\/ANE.0000000000000165","volume":"118","author":"DJ Eleveld","year":"2014","unstructured":"Eleveld DJ, Proost JH, Cortinez LI, Absalom AR, Struys MM. A general purpose pharmacokinetic model for propofol. Anesth Analg. 2014;118(6):1221\u201337.","journal-title":"Anesth Analg"},{"issue":"11","key":"3040_CR48","doi-asserted-by":"publisher","first-page":"739","DOI":"10.2165\/11592890-000000000-00000","volume":"50","author":"S van Kralingen","year":"2011","unstructured":"van Kralingen S, Diepstraten J, Peeters MY, Deneer VH, van Ramshorst B, Wiezer RJ, et al. Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients. Clin Pharmacokinet. 2011;50(11):739\u201350.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"3040_CR49","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/JTN.0000000000000022","volume":"21","author":"AE Shearin","year":"2014","unstructured":"Shearin AE, Patanwala AE, Tang A, Erstad BL. Predictors of hypotension associated with propofol in trauma patients. J Trauma Nurs. 2014;21(1):4\u20138.","journal-title":"J Trauma Nurs"},{"issue":"8","key":"3040_CR50","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s40261-013-0101-1","volume":"33","author":"PA Valitalo","year":"2013","unstructured":"Valitalo PA, Ahtola-Satila T, Wighton A, Sarapohja T, Pohjanjousi P, Garratt C. Population pharmacokinetics of dexmedetomidine in critically ill patients. Clinical Drug Investigation. 2013;33(8):579\u201387.","journal-title":"Clinical Drug Investigation"},{"issue":"8","key":"3040_CR51","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s40262-017-0507-7","volume":"56","author":"MAS Weerink","year":"2017","unstructured":"Weerink MAS, Struys M, Hannivoort LN, Barends CRM, Absalom AR, Colin P. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clin Pharmacokinet. 2017;56(8):893\u2013913.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"3040_CR52","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00540-017-2399-y","volume":"31","author":"B Xu","year":"2017","unstructured":"Xu B, Zhou D, Ren L, Shulman S, Zhang X, Xiong M. Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. J Anesth. 2017;31(6):813\u201320.","journal-title":"J Anesth"},{"issue":"12","key":"3040_CR53","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s00228-015-1948-2","volume":"71","author":"LI Cortinez","year":"2015","unstructured":"Cortinez LI, Anderson BJ, Holford NH, Puga V, de la Fuente N, Auad H, et al. Dexmedetomidine pharmacokinetics in the obese. Eur J Clin Pharmacol. 2015;71(12):1501\u20138.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"3040_CR54","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.bja.2018.01.040","volume":"120","author":"A Rolle","year":"2018","unstructured":"Rolle A, Paredes S, Cortinez LI, Anderson BJ, Quezada N, Solari S, et al. Dexmedetomidine metabolic clearance is not affected by fat mass in obese patients. Br J Anaesth. 2018;120(5):969\u201377.","journal-title":"Br J Anaesth"},{"issue":"1","key":"3040_CR55","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/00000542-198461010-00006","volume":"61","author":"DJ Greenblatt","year":"1984","unstructured":"Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology. 1984;61(1):27\u201335.","journal-title":"Anesthesiology."},{"issue":"10","key":"3040_CR56","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s40262-014-0166-x","volume":"53","author":"MJ Brill","year":"2014","unstructured":"Brill MJ, van Rongen A, Houwink AP, Burggraaf J, van Ramshorst B, Wiezer RJ, et al. Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers. Clin Pharmacokinet. 2014;53(10):931\u201341.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"3040_CR57","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1097\/CCM.0000000000003291","volume":"46","author":"J Katz","year":"2018","unstructured":"Katz J, Greenberg S. Etomidate is NOT a first-line induction agent in critically ill patients: primum non nocere-above all, do no harm. Crit Care Med. 2018;46(9):1495\u20136.","journal-title":"Crit Care Med"},{"issue":"9","key":"3040_CR58","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1097\/CCM.0000000000003290","volume":"46","author":"GC Lynde","year":"2018","unstructured":"Lynde GC, Jabaley CS. Etomidate is a first-line induction agent in critically ill patients. Crit Care Med. 2018;46(9):1492\u20134.","journal-title":"Crit Care Med"},{"issue":"2","key":"3040_CR59","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1378\/chest.14-1012","volume":"147","author":"WJ Gu","year":"2015","unstructured":"Gu WJ, Wang F, Tang L, Liu JC. Single-dose etomidate does not increase mortality in patients with sepsis: a systematic review and meta-analysis of randomized controlled trials and observational studies. Chest. 2015;147(2):335\u201346.","journal-title":"Chest."},{"issue":"9686","key":"3040_CR60","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(09)60949-1","volume":"374","author":"P Jabre","year":"2009","unstructured":"Jabre P, Combes X, Lapostolle F, Dhaouadi M, Ricard-Hibon A, Vivien B, et al. Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial. Lancet (London, England). 2009;374(9686):293\u2013300.","journal-title":"Lancet (London, England)"},{"issue":"4","key":"3040_CR61","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1177\/0091270010369242","volume":"51","author":"K Kaneda","year":"2011","unstructured":"Kaneda K, Yamashita S, Woo S, Han TH. Population pharmacokinetics and pharmacodynamics of brief etomidate infusion in healthy volunteers. J Clin Pharmacol. 2011;51(4):482\u201391.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"3040_CR62","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2174\/15748863113089990045","volume":"8","author":"BR Traylor","year":"2013","unstructured":"Traylor BR, Patanwala AE, Sakles JC, Erstad BL. Under-dosing of etomidate for rapid sequence intubation in the emergency department. Curr Drug Saf. 2013;8(4):253\u20136.","journal-title":"Curr Drug Saf"},{"issue":"17","key":"3040_CR63","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.2146\/ajhp120673","volume":"70","author":"A Amini","year":"2013","unstructured":"Amini A, Faucett EA, Watt JM, Amini R, Sakles JC, Rhee P, et al. Effect of a pharmacist on timing of postintubation sedative and analgesic use in trauma resuscitations. Am J Health-Syst Pharmacy. 2013;70(17):1513\u20137.","journal-title":"Am J Health-Syst Pharmacy"},{"issue":"3","key":"3040_CR64","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1097\/CCM.0b013e31819b8608","volume":"37","author":"RP Patel","year":"2009","unstructured":"Patel RP, Gambrell M, Speroff T, Scott TA, Pun BT, Okahashi J, et al. Delirium and sedation in the intensive care unit: survey of behaviors and attitudes of 1384 healthcare professionals. Crit Care Med. 2009;37(3):825\u201332.","journal-title":"Crit Care Med"},{"issue":"3","key":"3040_CR65","doi-asserted-by":"publisher","first-page":"R84","DOI":"10.1186\/cc11342","volume":"16","author":"JT Swan","year":"2012","unstructured":"Swan JT, Fitousis K, Hall JB, Todd SR, Turner KL. Antipsychotic use and diagnosis of delirium in the intensive care unit. Critical care (London, England). 2012;16(3):R84.","journal-title":"Critical care (London, England)"},{"issue":"6","key":"3040_CR66","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2165\/00003088-199937060-00001","volume":"37","author":"S Kudo","year":"1999","unstructured":"Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet. 1999;37(6):435\u201356.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"3040_CR67","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2165\/00003088-200241020-00006","volume":"41","author":"E Yukawa","year":"2002","unstructured":"Yukawa E, Hokazono T, Yukawa M, Ichimaru R, Maki T, Matsunaga K, et al. Population pharmacokinetics of haloperidol using routine clinical pharmacokinetic data in Japanese patients. Clin Pharmacokinet. 2002;41(2):153\u20139.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"3040_CR68","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S0002-9149(97)00888-6","volume":"81","author":"ND Sharma","year":"1998","unstructured":"Sharma ND, Rosman HS, Padhi ID, Tisdale JE. Torsades de Pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol. 1998;81(2):238\u201340.","journal-title":"Am J Cardiol"},{"issue":"7","key":"3040_CR69","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2165\/00003088-200140070-00003","volume":"40","author":"CL DeVane","year":"2001","unstructured":"DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet. 2001;40(7):509\u201322.","journal-title":"Clin Pharmacokinet"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-020-03040-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-020-03040-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-020-03040-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T19:44:20Z","timestamp":1623095060000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-020-03040-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,8]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3040"],"URL":"https:\/\/doi.org\/10.1186\/s13054-020-03040-z","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,8]]},"assertion":[{"value":"10 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BLE: No conflicts of interest.JFB: Consultant for Wolters Kluwer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"315"}}